vs
agilon health, inc.（AGL）与CRYO CELL INTERNATIONAL INC（CCEL）财务数据对比。点击上方公司名可切换其他公司
agilon health, inc.的季度营收约是CRYO CELL INTERNATIONAL INC的200.1倍（$1.6B vs $7.8M）。agilon health, inc.净利率更高（-12.0% vs -48.7%，领先36.6%）。agilon health, inc.同比增速更快（3.1% vs -2.3%）。CRYO CELL INTERNATIONAL INC自由现金流更多（$1.2M vs $-23.5M）。过去两年CRYO CELL INTERNATIONAL INC的营收复合增速更高（-0.1% vs -1.1%）
agilon health是一家美国医疗保健企业，主要与基层医疗服务提供者合作，为联邦医疗保险覆盖的老年群体提供价值导向型医疗解决方案，为医生提供行政支持、临床工具及风险管理框架，在提升诊疗效果的同时降低医疗成本，业务覆盖美国20余个州。
Cryo-Cell国际是一家脐带血库企业，由丹·理查德于1989年创立，是全球首家分离并储存干细胞的民营脐带血库，总部位于佛罗里达州奥兹马尔，地处坦帕市郊。
AGL vs CCEL — 直观对比
营收规模更大
AGL
是对方的200.1倍
$7.8M
营收增速更快
AGL
高出5.3%
-2.3%
净利率更高
AGL
高出36.6%
-48.7%
自由现金流更多
CCEL
多$24.7M
$-23.5M
两年增速更快
CCEL
近两年复合增速
-1.1%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $1.6B | $7.8M |
| 净利润 | $-188.9M | $-3.8M |
| 毛利率 | — | 77.9% |
| 营业利润率 | -12.3% | -50.6% |
| 净利率 | -12.0% | -48.7% |
| 营收同比 | 3.1% | -2.3% |
| 净利润同比 | -78.5% | -105.1% |
| 每股收益（稀释后） | — | $-0.46 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AGLCCEL
| Q4 25 | $1.6B | $7.8M | ||
| Q3 25 | $1.4B | $7.8M | ||
| Q2 25 | $1.4B | $7.9M | ||
| Q1 25 | $1.5B | $8.0M | ||
| Q4 24 | $1.5B | $8.0M | ||
| Q3 24 | $1.5B | $8.1M | ||
| Q2 24 | $1.5B | $8.0M | ||
| Q1 24 | $1.6B | $7.9M |
净利润AGLCCEL
| Q4 25 | $-188.9M | $-3.8M | ||
| Q3 25 | $-110.2M | $749.4K | ||
| Q2 25 | $-104.4M | $355.8K | ||
| Q1 25 | $12.1M | $282.9K | ||
| Q4 24 | $-105.8M | $-1.9M | ||
| Q3 24 | $-117.6M | $1.1M | ||
| Q2 24 | $-30.7M | $655.8K | ||
| Q1 24 | $-6.1M | $556.2K |
毛利率AGLCCEL
| Q4 25 | — | 77.9% | ||
| Q3 25 | — | 77.0% | ||
| Q2 25 | — | 76.6% | ||
| Q1 25 | — | 75.1% | ||
| Q4 24 | — | 78.4% | ||
| Q3 24 | — | 73.6% | ||
| Q2 24 | — | 74.8% | ||
| Q1 24 | — | 73.7% |
营业利润率AGLCCEL
| Q4 25 | -12.3% | -50.6% | ||
| Q3 25 | -9.1% | 24.3% | ||
| Q2 25 | -8.3% | 18.8% | ||
| Q1 25 | -1.4% | 13.3% | ||
| Q4 24 | -7.1% | -1.5% | ||
| Q3 24 | -9.2% | 17.2% | ||
| Q2 24 | -2.9% | 17.3% | ||
| Q1 24 | -0.4% | 10.5% |
净利率AGLCCEL
| Q4 25 | -12.0% | -48.7% | ||
| Q3 25 | -7.7% | 9.6% | ||
| Q2 25 | -7.5% | 4.5% | ||
| Q1 25 | 0.8% | 3.5% | ||
| Q4 24 | -6.9% | -23.2% | ||
| Q3 24 | -8.1% | 13.0% | ||
| Q2 24 | -2.1% | 8.2% | ||
| Q1 24 | -0.4% | 7.1% |
每股收益（稀释后）AGLCCEL
| Q4 25 | — | $-0.46 | ||
| Q3 25 | — | $0.09 | ||
| Q2 25 | — | $0.04 | ||
| Q1 25 | — | $0.03 | ||
| Q4 24 | — | $-0.23 | ||
| Q3 24 | — | $0.13 | ||
| Q2 24 | — | $0.08 | ||
| Q1 24 | — | $0.07 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $173.7M | $3.3M |
| 总债务越低越好 | $35.0M | $8.4M |
| 股东权益账面价值 | $126.7M | $-18.6M |
| 总资产 | $1.3B | $61.7M |
| 负债/权益比越低杠杆越低 | 0.28× | — |
8季度趋势，按日历期对齐
现金及短期投资AGLCCEL
| Q4 25 | $173.7M | $3.3M | ||
| Q3 25 | $171.7M | $3.2M | ||
| Q2 25 | $171.4M | $4.4M | ||
| Q1 25 | $136.9M | $3.5M | ||
| Q4 24 | $188.2M | $3.5M | ||
| Q3 24 | $148.2M | $2.1M | ||
| Q2 24 | $109.5M | $1.5M | ||
| Q1 24 | $111.7M | $979.6K |
总债务AGLCCEL
| Q4 25 | $35.0M | $8.4M | ||
| Q3 25 | — | $8.4M | ||
| Q2 25 | — | $8.4M | ||
| Q1 25 | — | $8.5M | ||
| Q4 24 | — | $8.5M | ||
| Q3 24 | — | $8.5M | ||
| Q2 24 | — | $8.5M | ||
| Q1 24 | — | $8.6M |
股东权益AGLCCEL
| Q4 25 | $126.7M | $-18.6M | ||
| Q3 25 | $306.1M | $-14.8M | ||
| Q2 25 | $408.9M | $-15.6M | ||
| Q1 25 | $500.3M | $-14.7M | ||
| Q4 24 | $471.0M | $-13.2M | ||
| Q3 24 | $574.9M | $-9.6M | ||
| Q2 24 | $676.6M | $-10.7M | ||
| Q1 24 | $689.3M | $-10.3M |
总资产AGLCCEL
| Q4 25 | $1.3B | $61.7M | ||
| Q3 25 | $1.6B | $63.2M | ||
| Q2 25 | $1.7B | $64.4M | ||
| Q1 25 | $1.9B | $64.4M | ||
| Q4 24 | $1.7B | $64.7M | ||
| Q3 24 | $2.1B | $62.9M | ||
| Q2 24 | $2.2B | $62.6M | ||
| Q1 24 | $2.3B | $61.7M |
负债/权益比AGLCCEL
| Q4 25 | 0.28× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-20.5M | $1.3M |
| 自由现金流经营现金流 - 资本支出 | $-23.5M | $1.2M |
| 自由现金流率自由现金流/营收 | -1.5% | 15.5% |
| 资本支出强度资本支出/营收 | 0.2% | 0.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-119.0M | $5.2M |
8季度趋势，按日历期对齐
经营现金流AGLCCEL
| Q4 25 | $-20.5M | $1.3M | ||
| Q3 25 | $-18.2M | $2.5M | ||
| Q2 25 | $-35.1M | $707.0K | ||
| Q1 25 | $-32.0M | $954.1K | ||
| Q4 24 | $16.4M | $2.2M | ||
| Q3 24 | $-7.7M | $2.4M | ||
| Q2 24 | $-18.7M | $1.8M | ||
| Q1 24 | $-47.8M | $-356.9K |
自由现金流AGLCCEL
| Q4 25 | $-23.5M | $1.2M | ||
| Q3 25 | $-21.3M | $2.5M | ||
| Q2 25 | $-38.3M | $644.6K | ||
| Q1 25 | $-35.8M | $892.0K | ||
| Q4 24 | $13.2M | $2.1M | ||
| Q3 24 | $-11.2M | $2.3M | ||
| Q2 24 | $-22.0M | $21.5K | ||
| Q1 24 | $-50.9M | $-814.6K |
自由现金流率AGLCCEL
| Q4 25 | -1.5% | 15.5% | ||
| Q3 25 | -1.5% | 31.9% | ||
| Q2 25 | -2.7% | 8.1% | ||
| Q1 25 | -2.3% | 11.2% | ||
| Q4 24 | 0.9% | 26.8% | ||
| Q3 24 | -0.8% | 27.9% | ||
| Q2 24 | -1.5% | 0.3% | ||
| Q1 24 | -3.2% | -10.4% |
资本支出强度AGLCCEL
| Q4 25 | 0.2% | 0.9% | ||
| Q3 25 | 0.2% | 0.5% | ||
| Q2 25 | 0.2% | 0.8% | ||
| Q1 25 | 0.3% | 0.8% | ||
| Q4 24 | 0.2% | 0.1% | ||
| Q3 24 | 0.2% | 2.3% | ||
| Q2 24 | 0.2% | 21.8% | ||
| Q1 24 | 0.2% | 5.8% |
现金转化率AGLCCEL
| Q4 25 | — | — | ||
| Q3 25 | — | 3.38× | ||
| Q2 25 | — | 1.99× | ||
| Q1 25 | -2.64× | 3.37× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 2.32× | ||
| Q2 24 | — | 2.70× | ||
| Q1 24 | — | -0.64× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AGL
| Medical Services | $1.6B | 100% |
| Other Operating | $2.5M | 0% |
CCEL
暂无分部数据
